AAOS Pushes for Evidence-Based Orthobiologics Amid Growing Market Hype
Event summary
- AAOS held its 2026 Orthobiologics Symposium in Seattle on August 17, 2026, emphasizing evidence-based approaches to orthobiologic therapies.
- Experts agreed that while some orthobiologic therapies show promise, many lack sufficient evidence for widespread use.
- Keynote speaker Thom Mayer, MD, medical director for the NFL Players Association, stressed the importance of shared decision-making in evaluating treatments.
- AAOS committed to advancing evidence-based orthobiologics through research, clinical practice guidelines, and patient resources.
The big picture
The AAOS symposium underscores the growing tension between market hype and scientific rigor in the orthobiologics sector. As patient interest rises, the need for transparent, evidence-based guidelines becomes critical. The involvement of professional sports organizations highlights the high-stakes nature of treatment decisions for elite athletes, where both performance and safety are paramount. AAOS' role in shaping the future of orthobiologics will be pivotal in ensuring that innovation is grounded in robust science.
What we're watching
- Evidence Gaps
- How the pace of clinical research will determine the adoption of orthobiologic therapies.
- Regulatory Compliance
- Whether AAOS' emphasis on evidence-based approaches will influence regulatory standards for orthobiologics.
- Market Dynamics
- The impact of AAOS' guidelines on the competitive landscape of orthobiologic treatments.
Related topics